Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

1.702 -0.028 (-1.65%)
Streaming Delayed Price Updated: 10:35 AM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
COMPASS Pathways Is Accelerating Patient Access To Evidence-Based Innovation In Mental Health Care
The Current Landscape Of Mental Health Is Failing Patients 
Via Benzinga
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
Via ACCESSWIRE
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions... 
Via Benzinga
EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into a supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics.  
Via Benzinga
Topics Supply Chain
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
BioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Via ACCESSWIRE
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Via ACCESSWIRE
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying – the “smart money” – can also be an indicator to evaluate... 
Via Benzinga
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
Via ACCESSWIRE
Over $4M Bet On Yellow Corp? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher on Friday, also recording gains for the week. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. 
Via Benzinga
$5.7M Bet On This Tech Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher on Tuesday, recording gains for the 12th straight session. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Why Metropolitan Bank Holding Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) jumped 69% to $22.59 after the company announced it reached a settlement with the SEC. 
Via Benzinga
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
Via ACCESSWIRE
BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered
BioRestorative Therapies Inc (NASDAQ: BRTX) shares are trading lower by 17.13% to $2.95 Tuesday morning after the company announced a $2.1 million registered direct offe 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
Via ACCESSWIRE
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumb 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged
BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar disc disease,... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
BioResorative CEO is Featured in An Interview With SmallCaps Daily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.